Disease · MONDO_0006500

hemangioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hemangioma. Diseases, record MONDO_0006500. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006500

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hemangioma; Open Targets
Open Targets ID: MONDO_0006500; Open Targets
Other names: benign hemangioma, hemangioma, benign; Open Targets
Disease Ontology: DOID:255; Disease Ontology
MeSH: D006391; MeSH
NCI Thesaurus: C3085; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 10 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PROPRANOLOL	CHEMBL27	Small molecule	Approval	EMA Human Drugs	6	5	5	Drugs and targets
SODIUM TETRADECYL SULFATE	CHEMBL1200354	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ATENOLOL	CHEMBL24	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TIMOLOL MALEATE	CHEMBL1200870	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TIMOLOL	CHEMBL499	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LEUPROLIDE	CHEMBL1201199	Protein	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Beta-1 adrenergic receptor	4	Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	3	Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	1	Gonadotropin-releasing hormone receptor agonist	Unknown	https://conductscience.org/library/genes/2798	Drugs and targets
VEGFA	Vascular endothelial growth factor A, long form	1	Vascular endothelial growth factor A inhibitor	Phase 1	https://conductscience.org/library/genes/7422	Drugs and targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01056341	Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy	Phase 2/3	512	2014-06-24	Infantile Hemangioma	PROPRANOLOL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02913612	Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)	Phase 2	105	2022-11-15	Infantile Hemangioma	TIMOLOL MALEATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00967226	Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas	Phase 2	19	2016-02-24	Hemangioma of Infancy	PREDNISOLONE, PROPRANOLOL	Its record names the disease	ClinicalTrials.gov
NCT01873131	A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn	Not applicable	126		Hemangioma	TIMOLOL MALEATE	Its record names the disease	ClinicalTrials.gov
NCT04684667	''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"	Phase 2	100		Infantile Hemangioma	PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT01512173	Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo	Phase 2	82		Infantile Hemangioma	PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT03237637	Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas	Phase 3	60		Infantile Hemangioma	ATENOLOL, PROPRANOLOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00004436	Randomized Study of Hormonal Regulation of Infantile Hemangioma	Not applicable	30		Hemangioma	LEUPROLIDE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00312520	Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy	Phase 3	20		Hemangiomas	METHYLPREDNISOLONE, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT00089765	Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome	Phase 1	5		Von Hippel-Lindau Syndrome	RANIBIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
0.25% Timolol Treatment vs 0.5% Timolol Treatment: Comparison of Partial Response of Hemangioma Color From Baseline to 180 Days, Within Each Treatment Arm	32 of 44	34 of 49	93	NCT02913612	Trial comparisons
0.25% Timolol Treatment vs 0.5% Timolol Treatment: Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm	24 of 44	28 of 47	91	NCT02913612	Trial comparisons
Propranolol vs Prednisolone: serious adverse events	1 of 11	5 of 8	19	NCT00967226	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25693013	RESULT	1	PubMed
24526257	DERIVED	1	PubMed
24347141	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006500

GET https://conductscience.org/api/diseases/v1/MONDO_0006500/drugs

API reference For AI assistants